Kamal Patel, MD
Hematology & Oncology · Little Rock, ARNPI 1598747164
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Pfizer at 48.8% of the total. Reporting peaked in 2019 at $1,487 and has fallen 94.5% since, to $81 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 40 payments — averaging $51.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Kyowa Kirin, Inc.$195
- Seagen Inc.$132
- Johnson & Johnson$127
- Astellas Pharma US Inc$109
- Sirtex Medical Inc$103
- plus $383 from 12 others
Across 133 payments — averaging $5344.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$380K
- Pfizer$146K
- Helsinn Healthcare SA$119K
- Takeda Pharmaceuticals U.S.A., Inc.$46K
- AbbVie$11K
- Bristol Myers Squibb$8K
What the payments were for
- Speaking & faculty fees$94046%
- Food & beverage$70134%
- Education$41120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $1,002 |
| Kyowa Kirin, Inc. | 3 | $195 |
| Seagen Inc. | 5 | $132 |
| Johnson & Johnson | 3 | $127 |
| Astellas Pharma US Inc | 2 | $109 |
| Sirtex Medical Inc | 1 | $103 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Eisai Inc. | 4 | $70 |
| AstraZeneca | 2 | $47 |
| Sanofi | 2 | $33 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $21 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$940
- POTELIGEO$108
- SIR-Spheres Microspheres$103
How this compares
$2,052 in reported general payments places this provider in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DarzalexDaratumumab | 245 | $2,158,391 |
| CabometyxCabozantinib S-Malate | 43 | $1,269,946 |
| Neulasta OnproPegfilgrastim | 171 | $1,100,098 |
| MvasiBevacizumab-Awwb | 139 | $827,831 |
| TecentriqAtezolizumab | 71 | $757,867 |
| Lenalidomide | 52 | $753,114 |
| RevlimidLenalidomide | 33 | $586,747 |
| KeytrudaPembrolizumab | 49 | $554,586 |
| VenclextaVenetoclax | 65 | $499,690 |
| PomalystPomalidomide | 18 | $417,253 |
| JakafiRuxolitinib Phosphate | 16 | $382,527 |
| SprycelDasatinib | 19 | $329,964 |
| GazyvaObinutuzumab | 39 | $316,639 |
| AlymsysBevacizumab-Maly | 45 | $306,709 |
| ProcritEpoetin Alfa | 102 | $297,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonDarzalex, Procrit, Xarelto | $127 | $2,597,519543 claims |
| AstraZenecaCalquence, Imfinzi | $47 | $319,75623 claims |
| PfizerEliquis, Nyvepria | $1,002 | $220,363265 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Little Rock
- Frits van RheeLittle Rock$218K
- Appalanaidu SasapuLittle Rock$63K
- Peter EmanuelLittle Rock$53K
- Brad BaltzLittle Rock$25K
- Carolina SchinkeLittle Rock$23K
- Pooja MotwaniLittle Rock$21K
- Naveen YarlagaddaLittle Rock$18K
- Joseph BeckLittle Rock$16K
- Konstantinos ArnaoutakisLittle Rock$12K
- Abhijit GodboleLittle Rock$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.